Find a Clinical Trial

Acute Myeloid Leukemia (ECOG #E2906): Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by

HIV in Women: Toward defining self - HIV positive women, language, and Thompson’s theory of body image (1_PRO00000159)

HIV Testing: Use of microchip based assays to measure HIV viral load (2_PRO00000054)

Diabetes in Pregnant Women: Blood glucose monitoring system by Telcare in the management of a small cohort of pregnant patients with Type 1 and 2 diabetes (1_PRO00000723)

Chronic Genotype 1 or 4 Hepatitis C with HIV-1 co-infection/ GS-US-337-0115- A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks

HIV/AIDS: Felt-stigma and adherence in Hispanics LWHA: a study of a cross-cultural, cross-disciplinary approach: phase II (1_PRO00000305)

Hepatitis C in Pregnancy: An observational study of hepatitis C virus in pregnancy (1_PRO00000222)

Chronic HCV: AI452-032- Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir for treatment of chronic HCV infection with

OB/GYN: A randomized trial to prevent congenital cytomegalovirus infection (CMV) (1_PRO00000047)

Chronic Hepatitis C and Chronic Kidney Disease/ A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with

Pregnancy and Diabetes: Continuous glucose monitoring in apparently well controlled gestational diabetics with sonographic evidence of suboptimal glycemic control

Chronic Hepatitis C with HIV co-infection/ AI444-216-A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6)

Smoking Cessation/ Recruitment Feasibility Study for Reducing Postpartum Smoking among Low-income and Hispanic Women (1_PRO00000417)

Hepatitis C (AI452021): A phase 3 evaluation of daclatasvir in combination with peginterferon lambda-1a and ribavirin (RBV) or telaprevir in combination with peginterferon alfa-2a and RBV in patients with chronic

Hepatitis C and Compensated Cirrhosis: A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis (2_PRO00001435)

Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)

A RANDOMIZED PHASE II STUDY COMPARING CYTARABINE + DAUNORUBICIN (7+3) VS (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYTARABINE + DAUNORUBICIN + VENETOCLAX, AZACITIDINE + VENETOCLAX, AND (DAUNORUBICIN AND CYTARABINE) LIPOSOME + VENETOCLAX

A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL

A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

MyeloMATCH MASTER SCREENING AND REASSESSMENT PROTOCOL (MSRP) FOR TIER ADVANCEMENT IN THE NCI MYELOMATCH CLINICAL TRIALS

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease

COGNITIVE TRAINING FOR CANCER RELATED COGNITIVE IMPAIRMENT IN BREAST CANCER SURVIVORS: A MULTI-CENTER RANDOMIZED DOUBLE- BLINDED CONTROLLED TRIAL

PROSPECTIVE OBSERVATIONAL COHORT STUDY OF PATIENTS WITH METASTATIC HER-2+ BREAST CANCER AT RISK OF CARDIAC TOXICITY

SHORT TERM INTENSIFIED PEMBROLIZUMAB (KEYTRUDA) AND TIVOZANIB FOR HIGH-RISK RENAL CELL CARCINOMA - STRIKE

A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA